GLP-1 agonist drugs may improve survival in breast cancer.
(Lots of evidence in animal models shows calorie restriction slows cancer growth.)
Three large observational studies suggest GLP-1 drugs may improve survival in some breast cancer patients, including DCIS and HR-positive disease.
GLP-1 agonist drugs may improve survival in breast cancer.
(Lots of evidence in animal models shows calorie restriction slows cancer growth.)
A trio of large observational studies reported at the San Antonio Breast Cancer Symposium (SABCS) 2025 suggest that GLP-1 receptor agonists may improve outcomes in some women with breast cancer.
Two studies reported an overall survival benefit of GLP-1 use in certain patients with breast cancer, including those with ductal carcinoma in situ (DCIS) and invasive hormone receptor (HR)-positive nonmetastatic disease, and a third found improvements in a range of toxicities among patients receiving chemotherapy. Beyond Weight Loss: GLP-1s Show Promise in Breast Cancer (Medscape)